GEA
NVCR icon

Glen Eagle Advisors’s NovoCure NVCR Stock Holding History

Glen Eagle Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25
Closed -$2.9K – 1034
2021
Q3 		$2.9K Hold
25
– – ﹤0.01% 881
2021
Q2 		$5.55K Hold
25
– – ﹤0.01% 801
2021
Q1 		$3.31K Hold
25
– – ﹤0.01% 822
2020
Q4 		$4.33K Hold
25
– – ﹤0.01% 760
2020
Q3 		$2.78K Hold
25
– – ﹤0.01% 766
2020
Q2 		$1.48K Buy
+25
New +$1.64K ﹤0.01% 781

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glen Eagle Advisors's NVCR Position: Q4 2021 in Review

Glen Eagle Advisors sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 25 shares — an estimated $2.9K sold.

Glen Eagle Advisors first reported a position in NVCR in Q2 2020 and held it in 6 quarters. The position peaked at $5.55K in Q2 2021. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

  • Glen Eagle Advisors reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
  • Glen Eagle Advisors sold 25 NovoCure shares in Q4 2021, an estimated $2.9K.
  • Glen Eagle Advisors first reported a position in NovoCure in Q2 2020 and held it in 6 quarters.
  • Glen Eagle Advisors's NovoCure position peaked at $5.55K in Q2 2021.
  • 311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on Glen Eagle Advisors's 13F filing for Q4 2021, filed 13 Aug 2024.